Back
Incyte Corporation (INCY)
BiotechnologyINCY · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$116.75
−1.51%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$6.41
ROE
30.8%
Gross margin
52.8%
Debt/Equity
0.70x
Revenue growth
20.9%
Incyte Corporation — company intelligence
Earnings surprises
Q1 2026$1.81 vs $1.40 est+29.4%
Q4 2025$1.80 vs $1.97 est-8.5%
Q3 2025$2.26 vs $1.69 est+33.7%
Q2 2025$1.57 vs $1.50 est+4.7%
Analyst consensus · 35 analysts
16 Buy18 Hold1 Sell
Updated Jul 6, 2026
Insider activity · 90 days
22 buys8 sellsnet +133,033 shares
Mayes Patrick ASell 350 · Jul 2, 2026
Tray ThomasSell 477 · Jul 2, 2026
Stein Steven HSell 2,177 · Jul 2, 2026
Recent SEC filings
4 — Insider transaction reportJul 7, 2026
4 — Insider transaction reportJul 7, 2026
4 — Insider transaction reportJul 7, 2026
Latest news
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $99 — Benzinga · 3d ago
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio — Yahoo · 4d ago
Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion — Yahoo · 1w ago
1 Mid-Cap Stock to Research Further and 2 We Avoid — Yahoo · 1w ago
Top 10 Quant Stocks Of 2026 Up Nearly 70% — SeekingAlpha · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Incyte Corporation
Weekly undervalued picks (like INCY)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.